Ramandeep Singh files Form 144 to sell 29,494 LQDA shares (NASDAQ:LQDA)
Ramandeep Singh has filed a Form 144 to propose the sale of 29,494 shares of Liquidia Corp (NASDAQ:LQDA) stock, originating from a stock option exercise scheduled for May 21, 2026. The filing indicates Morgan Stanley Smith Barney LLC as the broker-dealer and NASDAQ as the market for the transaction. Additionally, the document notes a prior sale of 40,359 shares on March 13, 2026, which generated proceeds of $1,457,296.50.
Caligan Partners (LQDA) shifts 5,300 Liquidia shares in internal fund trade
Caligan Partners, through its managed entities and David Johnson, reported an internal fund transaction involving 5,300 shares of Liquidia Corp (LQDA) common stock. On May 19, 2026, purchases and sales of equal amounts occurred at $59.98 per share, indicating a reallocation between Caligan Funds rather than a change in overall exposure. Following these trades, Caligan-related entities indirectly held 8,133,651 Liquidia shares, while David Johnson directly held 18,396 shares.
Caligan Partners reports Liquidia stock transfer worth $317,894
Caligan Partners LP and David Edward Johnson, a director and 10% owner of Liquidia Corp (NASDAQ:LQDA), completed an internal transfer of 5,300 shares of common stock, valued at $317,894. This transaction involved an internal movement of shares between funds managed by Caligan, following which their indirect beneficial ownership in Liquidia totaled 8,138,951 shares, with Mr. Johnson directly owning an additional 18,396 shares. The company has seen significant success with its drug Yutrepia, leading several analysts to raise their price targets.
Liquidia Corp (LQDA) CEO sells 75K shares under 10b5-1 plan
Liquidia Corp CEO Roger Jeffs sold 75,000 shares of common stock in pre-arranged transactions between May 18-20, 2026, under a Rule 10b5-1 trading plan adopted in November 2025. The sales were executed at volume-weighted average prices ranging from $56.77 to $61.30 per share through entities he controls. Despite the sales, Jeffs retains a substantial indirect holding of over 1.1 million shares, a direct position, and significant unvested restricted stock units, indicating routine liquidity management rather than a major shift in insider sentiment.
Liquidia CEO Roger Jeffs sells $4.4m in LQDA stock
Liquidia CEO Roger Jeffs sold 75,000 shares of LQDA stock for approximately $4.42 million over three days in mid-May, executed under a Rule 10b5-1 trading plan. These sales occurred as Liquidia traded near its 52-week high, with the company demonstrating strong financial performance and positive analyst outlooks, including impressive gross profit margins and predicted continued profitability. Despite the sales, Jeffs and associated entities retain a significant stake in the company.
Liquidia(LQDA.US) Officer Sells US$4.42 Million in Common Stock
Liquidia (LQDA.US) officer JEFFS ROGER sold 75,000 shares of the company's common stock between May 18 and May 20, 2026. The shares were sold at an average price of $58.9068, totaling approximately $4.42 million. This transaction is considered a statement of changes in beneficial ownership of securities, which federal securities laws require insiders to report.
Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock
Liquidia CEO Roger Jeffs recently sold 25,000 shares of the company's stock for approximately $1.47 million, as part of a pre-arranged trading plan. This latest transaction continues a pattern of insider selling by Jeffs, although he still retains a significant stake of over a million shares. Despite the insider selling, Liquidia's stock is performing strongly, trading near its 12-month high and beating recent earnings and revenue estimates.
GSA Capital Partners LLP Increases Stock Holdings in Liquidia Corporation $LQDA
GSA Capital Partners LLP significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 63.6% in the fourth quarter, bringing its total holdings to 63,176 shares valued at $2.18 million. This increase reflects a generally positive analyst outlook, with Liquidia holding a "Moderate Buy" rating and an average target price of $49.33. The company also reported strong quarterly results, exceeding EPS and revenue expectations.
Liquidia Corp stock (US53634H1077): CEO share sale draws attention after powerful rally
Liquidia Corp's CEO, Roger Jeffs, recently sold over $4 million worth of company shares following a significant rally in the biopharmaceutical group's stock price. This transaction, along with an earlier sale in April 2026, signals personal profit-taking, although such insider sales can be driven by personal financial management rather than a change in company outlook. The company specializes in rare cardiopulmonary diseases and its stock performance is heavily influenced by clinical, regulatory, and competitive developments in the pulmonary hypertension field.
Why Liquidia (LQDA) Is Up 34.6% After Swinging To First-Quarter Profit - And What's Next
Liquidia Corporation reported a significant swing to profitability in Q1 2026, with revenues reaching US$132.87 million and a net income of US$52.86 million, contrasting sharply with a net loss a year prior. This financial improvement is attributed to strong YUTREPIA sales and better payer access. While the company's outlook is positive, with analytical forecasts projecting substantial growth, investors should consider potential risks related to reimbursement changes, manufacturing expansion, and IP pressures.
Why Liquidia (LQDA) Is Up 34.6% After Swinging To First-Quarter Profit - And What's Next
Liquidia Corporation reported a significant swing to profitability in Q1 2026, with revenues reaching US$132.87 million and net income of US$52.86 million, a substantial improvement from a loss in the previous year. This shift is attributed to improved payer access and early uptake of YUTREPIA, raising questions about the sustainability of these economics amidst evolving reimbursement programs and capacity investments. While analysts have optimistic projections for future revenues and earnings, there are also warnings about potential downsides and the complexity of valuation.
Liquidia Corp CEO Roger Jeffs sells $4.3m in company stock
Liquidia Corp CEO Roger Jeffs sold 75,000 shares of the company's common stock for approximately $4.3 million in mid-May, executed through a Rule 10b5-1 trading plan. The sales occurred as Liquidia shares traded near their 52-week high, following impressive recent financial results and positive analyst revisions. Jeffs continues to hold a significant number of shares both directly and indirectly after these transactions.
Liquidia (NASDAQ:LQDA) Raised to Strong-Buy at Wall Street Zen
Liquidia (NASDAQ:LQDA) has been upgraded to a "strong-buy" rating by Wall Street Zen, contributing to a generally bullish outlook from analysts. The company recently surpassed earnings and revenue expectations, driven by significant growth in revenue and increasing commercial adoption of its product, YUTREPIA. Insider transactions show both sales and purchases, while institutional investors have adjusted their stakes in the company.
Liquidia (LQDA) CEO Jeffs sells 75,000 shares via entities
Liquidia Corp CEO Roger Jeffs sold a total of 75,000 shares of common stock across three days (May 13-15, 2026) through entities he controls. These sales were executed under a pre-arranged Rule 10b5-1 plan, with volume-weighted average prices ranging from $56.2851 to $58.6226 per share. Following these transactions, Jeffs retains significant direct and indirect holdings, alongside multiple blocks of unvested restricted stock units.
Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares
Liquidia CEO Roger Jeffs sold 25,000 shares of the company's stock on May 15th for approximately $1.43 million, part of a series of insider sales conducted under a Rule 10b5-1 plan. Despite the insider selling, Liquidia's stock has shown strong performance, trading near its 52-week high after beating revenue and EPS expectations in its recent earnings report. Analysts have maintained mostly bullish ratings and raised price targets for the stock.
LQDA (NASDAQ) insiders sell via 10b5-1; $5.76M proposed sale
A Form 144 filing indicates a proposed sale of 100,000 shares of Liquidia Corp (LQDA) common stock by Morgan Stanley Smith Barney LLC on May 14, 2026, with an aggregate value of $5,759,000. Additionally, the filing details multiple completed 10b5-1 sales by Serendipity Biopharma LLC and Roger Jeffs in April and May 2026. This activity represents routine dispositions under established trading plans by affiliates and insiders, contributing to transparency in securities transactions.
HC Wainwright Issues Positive Outlook for Liquidia Earnings
HC Wainwright has increased its Q2 2026 EPS estimate for Liquidia (NASDAQ:LQDA) to $0.86 from $0.49 and maintained a "Buy" rating with a $67 price target. This positive outlook follows Liquidia's better-than-expected Q1 results, where the company reported an EPS of $0.52 and revenue of $132.87 million, surpassing analyst expectations. The stock has garnered significant analyst support, with several firms reiterating bullish ratings and raising price targets, contributing to a consensus "Moderate Buy" rating for Liquidia.
Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 318,893 Shares of Stock
Liquidia Director Stephen Bloch sold 318,893 shares of the company's stock for approximately $16.0 million, reducing his stake by 14.57%. This insider selling follows stronger-than-expected quarterly results, with the company beating EPS and revenue estimates and seeing significant year-over-year revenue growth. Analysts have largely maintained a "Moderate Buy" rating for LQDA, with several increasing price targets.
Canaan entity tied to Liquidia (LQDA) director sells 318,893 shares in open market
An entity affiliated with Canaan, and linked to Liquidia (LQDA) director Stephen M. Bloch, sold 318,893 shares of Liquidia common stock on May 11, 2026. These open-market transactions occurred at weighted average prices between the high $40s and low $50s per share. The Form 4 filing clarifies that investment decisions were made by Canaan Partners VIII LLC managers, not Bloch himself, who disclaims beneficial ownership except for his pecuniary interest.
Liquidia Corp CEO Roger Jeffs sells $3.44m in shares
Liquidia Corp CEO Roger Jeffs sold 75,000 shares of company stock for approximately $3.44 million through three transactions between May 8 and May 12, 2026. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred while Liquidia stock was trading near its 52-week high and has seen a 259% return over the past year. Despite the strong performance, InvestingPro analysis suggests the stock might be overvalued.
Liquidia Corp at Bank of America Global Healthcare Conference Transcript
This article provides a transcript from Liquidia Corp's appearance at the Bank of America Global Healthcare Conference. CFO and COO Mike Casseta and Chief Business Officer Jason Adair discuss the commercial launch and performance of their drug YUTREPIA for pulmonary arterial hypertension (PAH) and PHILD. The conversation covers initial results, expectations, and the future opportunities for the product.
Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Analysts have significantly upgraded their near-term forecasts for Liquidia Corporation (NASDAQ:LQDA), boosting revenue and earnings per share estimates for 2026. This positive revision, reflecting a more bullish outlook on the company's prospects, has also led to a 26% increase in the analysts' price target to US$63.75. The market has reacted favorably, with the share price gaining 41% in the last 7 days, as Liquidia is now expected to grow significantly faster than the wider industry.
Best Momentum Stocks to Buy for May 13th
Zacks Equity Research has identified three momentum stocks with a "strong buy" rank for May 13th: Liquidia Corporation (LQDA), Nexa Resources S.A. (NEXA), and Nucor Corporation (NUE). These companies exhibit strong momentum characteristics, with significant share gains over the last three months and improved earnings estimates in the past 60 days. Each stock has a Zacks Rank #1 and a Momentum Score of A.
Mitsubishi UFJ Asset Management Co. Ltd. Has $957,000 Stock Holdings in Liquidia Corporation $LQDA
Mitsubishi UFJ Asset Management Co. Ltd. significantly reduced its stake in Liquidia Corporation by 48% in the fourth quarter, holding 30,489 shares valued at $957,000. Despite this, other institutional investors increased their holdings, and Liquidia reported a strong first quarter, beating earnings and revenue expectations with YUTREPIA sales accelerating towards a $1 billion target by 2027. Wall Street analysts remain largely bullish on LQDA, raising price targets, though some insider selling has occurred.
Liquidia (NASDAQ:LQDA) CEO Sells $1,037,500.00 in Stock
Liquidia CEO Roger Jeffs sold 25,000 shares of the company's stock for $1,037,500.00 on May 11th, reducing his direct stake by 1.89%. This sale was part of a pre-arranged trading plan. The company recently reported strong quarterly results, with EPS and revenue exceeding expectations, driven by demand for YUTREPIA, leading to a rise in stock price and increased analyst price targets.
Liquidia Corp CEO Roger Jeffs sells $3.44m in shares
Liquidia Corp CEO Roger Jeffs sold 75,000 shares of the company's common stock for approximately $3.44 million across three transactions between May 8 and May 12, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan and occurred while Liquidia stock was trading near its 52-week high, having delivered a 259% return over the past year. Following these transactions, Jeffs retains significant direct and indirect holdings in the company.
[Form 4] Liquidia Corp Insider Trading Activity
Liquidia Corp CEO Roger Jeffs, through his affiliated entity Serendipity BioPharma LLC, reported open-market sales of 75,000 shares of Liquidia common stock across three days. These transactions, valued at over $3.4 million, were conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sales, Jeffs's entities still retain a significant holding of over 1.2 million indirect shares, alongside direct shares and unvested restricted stock units, suggesting a routine liquidity event rather than a substantial change in ownership.
These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia (NASDAQ: LQDA) reported stronger-than-expected first-quarter results, with an EPS of 52 cents and sales of $132.865 million, surpassing analyst estimates. Following these positive results, Wells Fargo and HC Wainwright & Co. analysts raised their price targets for Liquidia, maintaining their Overweight and Buy ratings, respectively. The company's CEO highlighted the continued strong uptake of YUTREPIA and its focus on expanding prostacyclin therapy for pulmonary and vascular diseases.
Liquidia Corporation (NASDAQ:LQDA) Q1 2026 Earnings Call Transcript
Liquidia Corporation reported strong Q1 2026 results, with YUTREPIA leading growth in the inhaled prostacyclin category. The company achieved its third consecutive quarter of profitability, with net product sales of $129.9 million and net income of $52.9 million. Liquidia is expanding its clinical programs for YUTREPIA and L606, aiming for $1 billion in net revenue by 2027, funded by operating cash flow.
Vanguard Group Inc. Raises Position in Liquidia Corporation $LQDA
Vanguard Group Inc. increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 1.3% in the fourth quarter, bringing its total holdings to over 4 million shares valued at $138.4 million. This comes after Liquidia reported strong first-quarter earnings and revenue, driven by the commercialization of YUTREPIA, beating analyst expectations. Despite positive analyst sentiment and price target increases, some warnings suggest YUTREPIA's launch momentum might face competition-related ceilings.
Liquidia (LQDA) Hits All-Time High as Yutrepia Drives Swing to Profits
Liquidia (LQDA) stock reached an all-time high after reporting strong first-quarter earnings, driven by robust sales of its pulmonary hypertension treatment, Yutrepia. The company swung to a net income of $52.86 million from a loss in the prior year, with total revenues soaring by 4,328 percent. Yutrepia has garnered over 4,500 patient prescriptions since its June 2025 launch, indicating strong market adoption.
Liquidia, Beazer Homes, Circle Internet Group And Other Big Stocks Moving Higher On Monday
U.S. stocks saw a mostly higher trend on Monday, with the Nasdaq Composite climbing around 0.3%. Liquidia Corp (NASDAQ: LQDA) shares rose significantly after the company reported better-than-expected first-quarter financial results. Other notable movers included Beazer Homes USA Inc (NYSE: BZH) which gained on an acquisition proposal, and Circle Internet Group Inc (NYSE: CRCL) after raising $222 million for its new institutional blockchain Arc.
Liquidia (LQDA) shares rise after strong Q1 earnings and revenue beat
This article is a placeholder, as the content is currently empty. It indicates that Liquidia's (LQDA) shares rose following a strong first quarter earnings and revenue beat. Further details would be needed to provide a comprehensive summary.
Liquidia Q1 2026: Revenue Hits $132.9M, Up 4162% Year-Over-Year
Liquidia Corporation reported exceptional Q1 2026 results, with diluted earnings of $0.52 per share, significantly beating the $0.42 consensus estimate. The company achieved a remarkable 4162% year-over-year revenue increase to $132.9M, leading to a net income of $52.9M and a transition from loss to profitability. This strong performance, driven by commercial traction and patient growth, signals a significant maturation milestone for the specialty pharmaceutical company.
Liquidia (NASDAQ:LQDA) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS
Liquidia (NASDAQ:LQDA) announced its quarterly earnings, reporting an EPS of $0.52, which surpassed analyst estimates of $0.41 by $0.11. The company also experienced a significant year-over-year revenue increase of 4,187.1%. Despite the positive earnings surprise and stock uptick, Liquidia recorded a negative net margin and return on equity, alongside notable insider selling from its CFO and a director.
Liquidia Corp 1Q 2026: Revenue $132.87M, Net income $52.86M, EPS $0.52— 10-Q Summary
Liquidia Corp reported strong first-quarter 2026 results, driven by the commercial launch of YUTREPIA. The company posted revenue of $132.87M and net income of $52.86M, a significant increase from the previous year. Diluted EPS reached $0.52, marking a substantial turnaround from a loss in the prior-year quarter.
Earnings Flash (LQDA) Liquidia Corporation Reports Q1 Revenue $132.9M, Vs. FactSet Est of $119.4M
Liquidia Corporation announced its Q1 revenue reached $132.9 million, significantly surpassing FactSet's estimated $119.4 million. This indicates a stronger-than-expected financial performance for the company. The specific factors contributing to this revenue beat are not detailed in this flash report.
Liquidia Corporation Reports First Quarter 2026 Financial Results
Liquidia Corporation announced strong first-quarter 2026 financial results, reporting approximately $130 million in YUTREPIA sales and a net income of $52.9 million. The company achieved its third consecutive quarter of profitability, with YUTREPIA showing sustained uptake in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), attracting over 4,500 unique patient prescriptions. Liquidia is also advancing its clinical pipeline with ongoing Phase 4 and Phase 3 studies for YUTREPIA and L606, respectively.
Serendipity Biopharma (LQDA) files Form 144 for $4.23M sale
Serendipity Biopharma LLC has filed a Form 144 to report proposed sales of 100,000 shares of common stock, totaling an aggregate intended sale price of $4,228,000.00, scheduled for May 8, 2026. The filing also details multiple executed 10b5-1 sales between April 9, 2026, and May 7, 2026, indicating pre-arranged dispositions. Roger Jeffs is also noted for a significant sale on April 13, 2026.
Liquidia (LQDA) Set to Report Q1 Earnings with Strong Estimates
Liquidia Corp (LQDA) is expected to report its Q1 earnings on May 11th, with analysts projecting significant year-over-year increases in EPS and revenue. Despite strong growth prospects, the company faces challenges in profitability and has seen substantial insider selling, which may warrant caution from investors. Its GF Score of 70/100 highlights strong growth potential but also flags concerns about financial strength and profitability, with a high debt-to-equity ratio.
Liquidia CEO Roger Jeffs sells $3.07m in company stock By Investing.com
Liquidia CEO Roger Jeffs sold 75,000 shares of company stock worth approximately $3.07 million between May 5 and May 7, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sales, Jeffs retains significant direct and indirect holdings in the company, which has seen its stock deliver a 172% return over the past year.
Affiliate plans sales for LQDA (NASDAQ: LQDA) — multiple 10b5-1 trades listed
An affiliate of Liquidia Corporation (NASDAQ: LQDA) has filed a Form 144, indicating a proposed sale of 25,000 shares. The filing also details several completed 10b5-1 sales by SERENDIPITY BIOPHARMA LLC and one by ROGER JEFFS, occurring between April 9, 2026, and May 6, 2026, with individual proceeds listed for each transaction. This report is considered a routine notice rather than a new corporate action, highlighting transparency in insider trading activities.
Liquidia CEO Roger Jeffs sells $3.07m in company stock
Liquidia Corp's CEO, Roger Jeffs, sold 75,000 shares of company stock for approximately $3.07 million between May 5 and May 7, 2026. The sales were executed under a pre-arranged trading plan, with the stock trading near $42.28 and having delivered a 172% return over the past year. Despite the sales, Jeffs retains significant direct and indirect holdings in the company.
Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock
Liquidia (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the company's stock on May 5th at an average price of $40.10, totaling over $1 million. This sale was part of a pre-arranged Rule 10b5-1 trading plan and reduced his position by 1.76%. Jeffs has made several other significant sales in April and May, while analysts maintain a "Moderate Buy" rating for Liquidia with a target price of $43.44.
Liquidia (LQDA) CEO’s entity sells 75K shares under 10b5-1 plan
Liquidia Corp CEO Roger Jeffs, through Serendipity BioPharma LLC, sold 75,000 shares of common stock over three days under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at volume-weighted average prices between $40.10 and $42.09. Following these transactions, Jeffs retains significant holdings across Serendipity, a living trust, and direct ownership, in addition to substantial unvested RSU awards.
Liquidia (NASDAQ:LQDA) Raised to "Strong-Buy" at Zacks Research
Zacks Research has upgraded Liquidia (NASDAQ:LQDA) from a "hold" to a "strong-buy" rating. This upgrade is part of a broader positive sentiment from analysts, with the company currently holding a "Moderate Buy" consensus rating and an average price target of $43.44. The article also details recent insider selling activities and institutional investor movements, alongside the company's strong revenue growth and earnings beat in its latest quarterly report.
Analysts Are Optimistic We'll See A Profit From Liquidia Corporation (NASDAQ:LQDA)
This article discusses the optimistic outlook from analysts regarding Liquidia Corporation's potential to achieve profitability. It highlights the expected timeline for the company to turn a profit and provides an overview of analyst forecasts and stock performance.
Liquidia Corporation to Participate in Upcoming Investor Conferences
Liquidia Corporation announced its participation in two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the H.C. Wainwright 4th Annual Bioconnect Investor Conference on May 19, 2026. Company executives Michael Kaseta and Jason Adair will provide business updates and host one-on-one meetings at both events. Access to these events will be available on the "Investors" page of Liquidia’s website.
Liquidia executives take business update to two May investor events
Liquidia Corporation (NASDAQ: LQDA) announced its participation in two investor conferences in May 2026. COO & CFO Michael Kaseta and CBO Jason Adair will present company updates and hold one-on-one meetings at the BofA Securities Health Care Conference on May 13th and the H.C. Wainwright Bioconnect at NASDAQ on May 19th. Investors can access webcasts and replays on Liquidia's website.
Liquidia (Nasdaq:LQDA) - Stock Analysis
Liquidia Corporation (Nasdaq: LQDA) is a biopharmaceutical company focused on rare cardiopulmonary diseases, with its lead product YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's stock is currently trading at a 4.2% undervaluation according to analyst consensus and its earnings are forecasted to grow 33.04% per year, though significant insider selling has been noted alongside ongoing litigation risks. Recent updates highlight YUTREPIA's market traction, potential acquisition interest, and upcoming Q1 2026 earnings report, scheduled for May 11, 2026.
